Favorable Outcomes in Glioblastoma with Oligodendroglial Component After Treatment
Author Information
Author(s): Vordermark Dirk, Ruprecht Klemens, Rieckmann Peter, Roggendorf Wolfgang, Vince Giles H, Warmuth-Metz Monika, Kölbl Oliver, Flentje Michael
Primary Institution: University of Würzburg
Hypothesis
Patients with glioblastoma multiforme with an oligodendroglial component (GBMO) may have a better prognosis after combined post-operative radiotherapy and chemotherapy.
Conclusion
Patients with GBMO treated with post-operative radiotherapy and chemotherapy with ACNU/VM26 had a better prognosis than typically reported for GBM.
Supporting Evidence
- The median overall survival for GBMO patients was 26 months.
- The 2-year survival rate for these patients was 60%.
- 80% of patients received post-operative chemotherapy with ACNU and VM26.
Takeaway
This study looked at 10 patients with a specific type of brain tumor and found that those who got both radiation and chemotherapy lived longer than expected.
Methodology
The study analyzed overall and progression-free survival in 10 patients diagnosed with GBMO, reviewing their treatment and outcomes.
Potential Biases
There may be a risk of selection bias due to the small cohort and specific treatment protocols.
Limitations
The study is limited by the small number of patients and the retrospective nature of the analysis.
Participant Demographics
Median age was 54 years, with a range of 34 to 73 years; 90% underwent resection.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website